Surmodics, Inc. Expected to Earn FY2025 Earnings of $0.13 Per Share (NASDAQ:SRDX)

Surmodics, Inc. (NASDAQ:SRDX) – Research analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for Surmodics in a research report issued on Wednesday, October 9th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.13 for the year, up from their previous forecast of $0.10. The consensus estimate for Surmodics’ current full-year earnings is ($0.47) per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.24 EPS, Q1 2026 earnings at $0.24 EPS, Q2 2026 earnings at $0.11 EPS and FY2026 earnings at $0.75 EPS.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. The business had revenue of $30.34 million during the quarter, compared to analyst estimates of $30.32 million. Surmodics had a negative net margin of 1.16% and a positive return on equity of 3.88%.

Other equities analysts have also issued research reports about the company. StockNews.com assumed coverage on Surmodics in a research report on Monday. They set a “hold” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $50.00.

Surmodics Trading Down 0.2 %

SRDX opened at $38.57 on Monday. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The stock has a market cap of $550.39 million, a PE ratio of -385.70 and a beta of 1.20. The business has a 50 day moving average of $39.42 and a 200-day moving average of $37.33.

Hedge Funds Weigh In On Surmodics

Institutional investors and hedge funds have recently modified their holdings of the stock. Gabelli Funds LLC grew its holdings in shares of Surmodics by 393.7% during the second quarter. Gabelli Funds LLC now owns 260,200 shares of the company’s stock valued at $10,939,000 after buying an additional 207,500 shares during the last quarter. Gardner Lewis Asset Management L P purchased a new stake in Surmodics during the 2nd quarter valued at $8,531,000. Nisa Investment Advisors LLC increased its holdings in shares of Surmodics by 4,722.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 68,429 shares of the company’s stock worth $2,877,000 after purchasing an additional 67,010 shares in the last quarter. Versor Investments LP bought a new stake in shares of Surmodics in the 2nd quarter worth $2,723,000. Finally, Sagefield Capital LP purchased a new position in shares of Surmodics in the second quarter worth $2,350,000. 96.63% of the stock is currently owned by institutional investors.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).